Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Working Capital to Net Assets Ratio
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a Working Capital to Net Assets ratio of -103.0% as of December 2025. Working capital of $181.87 Million (current assets of $192.55 Million minus current liabilities of $10.68 Million) is measured against net assets of $-176.63 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hemab Therapeutics Holdings, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Hemab Therapeutics Holdings, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at -103.0%, reflecting working capital of $181.87 Million against net assets of $-176.63 Million USD. See Hemab Therapeutics Holdings, Inc. Common (COAG) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hemab Therapeutics Holdings, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Hemab Therapeutics Holdings, Inc. Common.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -103.0% | $181.87 Million | $-176.63 Million | $192.55 Million | $10.68 Million | ▼ -27.9 pp |
| 2024 | -75.1% | $86.55 Million | $-115.27 Million | $93.23 Million | $6.68 Million | — |